Gyre Therapeutics (GYRE) Finished Goods (2022 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Finished Goods of $4.2 million for Q1 2026, up 27.55% year-over-year from $3.3 million in Q1 2025, and up 44.61% quarter-over-quarter from $2.9 million in Q4 2025.
Gyre Therapeutics (GYRE) Finished Goods (2022 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Finished Goods for 5 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Finished Goods rose 27.55% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (up 27.55% YoY), while the FY2025 annual figure was $2.9 million, up 10.71% from the prior year.
- Finished Goods grew to $4.2 million in Q1 2026 per GYRE's latest filing, from $2.9 million in the prior quarter.
- Across five years, Finished Goods topped out at $4.2 million in Q1 2026 and bottomed at $1.4 million in Q4 2023.
- Historically, Finished Goods has averaged $2.5 million across 5 years, with a median of $2.6 million in 2024.
- Annual changes were most pronounced in 2023 — Finished Goods slipped 2.43% — and 2025, when it surged 122.77%.
- Gyre Therapeutics' Finished Goods stood at $1.4 million in 2022, then dropped by 2.43% to $1.4 million in 2023, then jumped by 91.5% to $2.6 million in 2024, then climbed by 10.71% to $2.9 million in 2025, then soared by 44.61% to $4.2 million in 2026.
- Business Quant data shows GYRE's Finished Goods at $4.2 million in Q1 2026, $2.9 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.94 Mn |
| Mar 31, 2026 | 4.19 Mn |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 3.32 Mn |
| Jun 30, 2025 | 3.44 Mn |
| Mar 31, 2025 | 3.28 Mn |
| Dec 31, 2024 | 2.61 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 1.40 Mn |